The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.
Mastermind Genomic Landscapes inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.
Genomenon means “born out of need” in ancient Greek, which perfectly describes Genomenon’s beginnings.
In his clinical practice and genomic research, co-founder Dr. Mark Kiel was frustrated with the painfully slow and time-consuming process of manual curation. Interpretation of genomic data resulting from next-generation DNA sequencing (NGS) was inefficient and error-prone due to the manual effort required to search and analyze the rapidly growing body of medical literature for disease-related genes and variants.
Genomenon was founded to address this pressing need for faster, more comprehensive variant interpretation by combining expert curation with unique machine learning methods designed to keep up with the pace of new publications and present the most relevant information to researchers.
Mark found like-minded experts dedicated to connecting patient DNA data with the billions of dollars worth of medical research that was previously impossible to organize at scale, and too challenging to interpret quickly and accurately for clinical genomics.
The Genomenon team built the Mastermind Genomic Search Engine, which contains all the disease-gene-variant-phenotype-therapy relationships found across the scientific literature. The technology developed to accomplish this feat is revolutionizing the way genetic and cancer diagnoses and discoveries are made. Mastermind makes it easy to get rapid insight into relevant literature for clinical decision-making, genomic research, and pharmaceutical drug discovery.
Today, co-founders Kiel and Steve Schwartz continue to drive the scientific and technological development of Mastermind, which now empowers scientists and researchers at pharmaceutical companies, clinical labs, and universities to more thoroughly understand diseases at a molecular level. Thousands of doctors in over 100 countries are using Mastermind to rapidly connect their patient’s variants with the published genomic research to more effectively treat cancer patients and diagnose babies with rare diseases.
Genomenon is headquartered in Ann Arbor, Michigan.
Mike Klein CEO
With over 25 years of developing, building and growing 4 different high tech companies, Mike raised over $50M in capital and had several successful investor exits.
Mark J. Kiel MD, PhD CSO & Co-Founder
Mark has extensive experience in genome-sequencing and clinical data analysis underlying the vision and technology driving the Genomenon suite of software tools.
Steve Schwartz CTO & Co-founder
Steve co-founded several successful web-based software start-ups. He brings to the team deep domain expertise and extensive start-up experience.
Candace Chapman Vice President of Marketing
Candace has 25 years experience in enterprise and high-tech marketing and brings both strategic leadership and tactical execution to the team.
Dave Anstey VP, Sales & Business Development
Dave has over 22 years experience selling scientific software with a track record of building successful sales teams and meaningful customer relationships.
Brittnee Jones, PhD Director of Customer Success
Brittnee has spent over a decade building and leading customer success teams across the NGS space, ensuring rapid product adaption and maximal value for customers.
Lianna Cecil Sr. Controller
Lianna’s experience includes over a decade working with start-ups and technology companies. She oversees all areas of finance, accounting and HR.
Kojo Elenitoba-Johnson, MD CO-FOUNDER & ADVISOR
Kojo is the Director for Precision and Computational Diagnostics at University of Pennsylvania Perelman School of Medicine and President of the Association of Molecular Pathology.
Megan Lim, MD, PhD CO-FOUNDER & ADVISOR
Megan is the Director of the Hematopathology and Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania.
Careers at Genomenon
Click on our current open positions to learn more and apply.
Genomenon seeks a Variant Analyst to critically evaluate the scientific literature, interpret the pathogenicity of genetic variants, and to help lead projects requested by clinical and pharmaceutical clients. View Job.
Genomenon is seeking a key contributor to the sales team to achieve our revenue growth goals. This position requires a sales-savvy, highly motivated person with experience in NGS and bioinformatics solution sales to help drive the company’s sales efforts. View Job.
We are seeking a field-based Genomic/Medical Science Liaison to support the commercial objectives of Genomenon. We are seeking an adaptable, self-starter who drives opportunities through peer-to-peer scientific conversations with KOLs and pharmaceutical partners. View Job.
When citing use of the Mastermind Genomic Search Engine, use the following text:
Mastermind Genomic Search Engine (https://www.genomenon.com/mastermind)
Details on the Mastermind research paper published in November of 2020:
Citation: Chunn LM, Nefcy DC, Scouten RW, Tarpey RP, Chauhan G, Lim MS, Elenitoba-Johnson KSJ, Schwartz SA, Kiel MJ. Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation. Front Genet. 2020 Nov 13;11:577152. doi: 10.3389/fgene.2020.577152. PMID: 33281875; PMCID: PMC7691534.